PALI Earnings Date: Nov 9, 2026 (Estimated) — Palisade Bio, Inc.
NASDAQ
Updated
When is PALI's next earnings date?
Palisade Bio, Inc. (PALI) is expected to report Q3 2026 earnings on Monday, November 9, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.06 on revenue of $465,302.
How did PALI do in its last earnings report?
In its most recent report on Aug 10, 2026 (Q2 2026), Palisade Bio, Inc. posted EPS of -$0.05 versus the -$0.05 estimate, a beat of 0.0%. Revenue was $500,000 against a $500,000 estimate. The stock's 1-day post-earnings move was +1.9%.
How much does PALI stock move after earnings?
PALI beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 1.6% (up or down) in the day after earnings.
About Palisade Bio, Inc.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-10 | Q2 2026 | -0.05 | -0.05 | +0.00% | $500,000 | ✅ Beat | +1.90% | +2.38% | -2.38% |
| 2026-05-12 | Q1 2026 | -0.04 | -0.05 | -25.00% | $0 | ❌ Miss | -2.60% | -5.73% | -7.29% |
| 2026-03-20 | Q4 2025 | -0.04 | 1.08 | +2800.00% | $0 | ✅ Beat | +1.06% | +5.82% | +48.15% |
| 2025-11-10 | Q3 2025 | -0.29 | -0.38 | -31.03% | $0 | ❌ Miss | +2.82% | +16.95% | +18.64% |
| 2025-08-11 | Q2 2025 | -0.53 | -0.58 | -9.43% | $0 | ❌ Miss | +1.35% | +8.24% | -27.16% |
| 2025-03-24 | Q4 2024 | -2.58 | -0.69 | +73.26% | $0 | ✅ Beat | -1.55% | -2.88% | +0.94% |
| 2024-08-12 | Q2 2024 | -2.93 | -3.32 | -13.31% | $0 | ❌ Miss | +1.09% | -1.37% | -0.55% |
| 2024-05-13 | Q1 2024 | -4.28 | -4.59 | -7.24% | $0 | ❌ Miss | +0.32% | -5.95% | -28.30% |
Showing last 8 quarters.